Background/Aims: Fabry disease is a treatable cause of chronic kidney disease (CKD) characterized by a genetic deficiency of α-galactosidase A. European Renal Best Practice (ERBP) recommends screening for Fabry disease in CKD patients. However, this is based on expert opinion and there are no reports of the prevalence of Fabry disease in stage 1-5 CKD. Hence, we investigated the prevalence of Fabry disease in CKD patients not receiving renal replacement therapy. Methods: This prospective study assessed α-galactosidase activity in dried blood spots in 313 stage 1-5 CKD patients, 167 males, between ages of 18-70 years whose etiology of CKD was unknown and were not receiving renal replacement therapy. The diagnosis was confirmed by GLA gene mutation analysis. Results: Three (all males) of 313 CKD patients (0.95%) were diagnosed of Fabry disease, for a prevalence in males of 1.80%. Family screening identified 8 aditional Fabry patients with CKD. Of a total of 11 Fabry patients, 7 were male and started enzyme replacement therapy and 4 were female. The most frequent manifestations in male patients were fatigue (100%), tinnitus, vertigo, acroparesthesia, hypohidrosis, cornea verticillata and angiokeratoma (all 85%), heat intolerance (71%), and abdominal pain (57%). The most frequent manifestations in female patients were fatigue and cornea verticillata (50%), and tinnitus, vertigo and angiokeratoma (25%). Three patients had severe episodic abdominal pain attacks and proteinuria, and were misdiagnosed as familial Mediterranean fever. Conclusions: The prevalence of Fabry disease in selected CKD patients is in the range found among renal replacement therapy patients, but the disease is diagnosed at an earlier, treatable stage. These data support the ERBP recommendation to screen for Fabry disease in patients with CKD of unknown origin.
Introduction
Fabry disease (OMIM # 301500) is a systemic X-linked disease characterized by the accumulation of globotriaosylceramide (GL-3) secondary to decreased activity of the lysosomal enzyme α-galactosidase A (α-GAL A, EC 3.2.1.22) [1] . The classical form of Fabry disease is observed in males with very low α-GAL A activity. Early manifestations of Fabry disease include episodic-intermittent pain crisis (acroparesthesia), vascular lesions (angiokeratomas), vascular tortuosity and corneal brown subepithelial linear deposits (cornea verticillata), hypohidrosis, and proteinuria [2] . In the following years, end-stage renal disease (ESRD), left ventricular hypertrophy (LVH) and occlusive cerebro-vascular events may occur [3, 4] , leading to early mortality when compared with age-and gendermatched healthy subjects [5] . Renal involvement can be seen in 48-55% of patients with Fabry disease and progresses to ESRD in most male patients [6] . However, the mean age at ESRD is 40 years both in males and in the females who do progress to this stage [2, 4] .
Disease presentation in female heterozygotes may be as severe as in males although women may also remain asymptomatic. The recent introduction of enzyme replacement therapy (ERT) to address the underlying pathophysiology of Fabry disease has focused attention on the early diagnosis of Fabry disease. Guidelines have been proposed for the recognition, evaluation, and surveillance of disease-associated morbidities, as well as therapeutic strategies, including ERT and other adjunctive therapies, to optimize patient outcomes [7] .
The prevalence of Fabry disease varies between 1/3100-1/117.000 in Europe [8] . However, there are no data on the prevalence of Fabry disease in stage 1-5 chronic kidney disease (CKD), despite an expert-based ERBP recommendation to screen for Fabry disease in such population [5] . Hence, we investigated the prevalence of Fabry disease in a CKD population in Turkey. We also defined the characteristics of CKD patients with Fabry disease and compared these with the results obtained in CKD patients without Fabry disease.
Materials and Methods
The study protocol was approved by the Medical Ethics Committee of GATA (Ankara, Turkey). Written informed consent was obtained from all subjects included in the study.
This prospective study recruited 313 stage 1-5 CKD patients not receiving renal replacement therapy (hemodialysis, peritoneal dialysis or transplantation) between December 2014 and March 2016 from 6 different region and 10 centers of Turkey. A review of medical records (including information on age; sex; weight; medications; primary disease of CKD) was undertaken. Inclusion criteria were: (1) stage 1-5 CKD patients not receiving renal replacement therapy ; (2) unknown etiology for CKD: patients did not have diabetic kidney disease or other kidney disease including glomerulonephritis, lupus nephritis, systemic vasculitis proven by kidney biopsy; (3) age 18-70 years; (4) patients gave written inform consent.
Four hundred and three patients were evaluated and 82 patients were excluded from the study: 47 refused to participate in the study, 24 had biopsy-proven glomerulopathies (including Table 1 . Demographic and Clinical data of CKD patients that were screened and of index patients found in the screening systemic lupus erythematosus and microscopic polyangiitis); and in 11 Fabry disease was considered very unlikely based on clinical manifestations. The remaining 313 CKD patients were enrolled in the study (Table  1) . Additionally, 73 family members from 3 index patients were also screened for Fabry Disease.
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in the upright sitting position after ≥5 minutes of rest using an Erka sphygmomanometer (PMS Instruments Limited, Berkshire, UK) with an appropriate cuff size. Two readings were recorded for each individual and the mean value was defined as the blood pressure. CKD patients with SBP and DBP >140 and >90 mmHg, respectively, or who were already on antihypertensive treatment were assumed to be hypertensive. Echocardiography M-mode and two-dimensional echocardiographic measurements were performed using a Vingmed System Five, Norway echocardiographic system equipped with 2.5-MHz transducers (Vingmed Sound, Horten, Norway) in accordance with methods recommended by the American Society of Echocardiography [9] . Cardiac mass was calculated by means of the Devereux and Reichek formula [10] . Left ventricular hypertrophy (LVH) was defined as left ventricular mass index (LVMI) ≥125 g/m 2 for men and ≥110 g/m 2 for women.
Screening and Diagnosis of Fabry Disease
Screening for Fabry was performed by assessing α-Gal A activity in dried blood spots (DBS). Blood was spotted directly onto the filter paper after lancet finger stick or venipuncture syringe draw. Blood spots were dried for at least 4 h at room temperature and were stored in sealed plastic bags at 4 °C for up to 1 week in a cabinet and at −20 °C with desiccant and a humidity indicator for longer periods [11] .
The cut-off to trigger confirmatory genetic analysis was 1.2 micromol/L/h in the CKD screening Fabry disease was confirmed by GLA gene mutation analysis. This cut-off point was determined from Receiver Operating Characteristic (ROC) testing by the Archimed Life Science GmbH laboratory. The same cut-off value was used for females and males. For the study of family members, genetic analysis both enzymatic analysis and genetic analysis were performed, given the higher probability of Fabry disease and the fact that enzymatic activity may be normal in Fabry females. Plasma lyso-Gl-3 levels were measured via tandem mass spectrometry method from DBS before ERT in 4 CKD patients with Fabry disease.
GLA Gene Sequencing GLA gene was sequenced using the MiSeq next generation sequencing (NGS) platform, a FDA approved diagnostic system (Illumina, San Diego, CA, USA). Genomic DNA was extracted according to the manufacturer's standard procedure using the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). All coding exons and their flanking splice site junctions were amplified using PCR primers, designed with PRIMER © -Primer Designer v.2.0 (Scientific & Educational Software programme) software. PCRs were validated by agarose gel electrophoresis. After PCR amplification, the libraries were prepared with the NexteraXT kit (Illumina Inc.), according to the manufacturer's instructions. Sequences were aligned to the hg19 genome within MiSeq Reporter software (Illumina Inc.). Visualization of the data was performed with IGV 2.3 (Broad Institute) software.
Biochemical analyses
Venous blood samples for biochemical analyses were drawn after an overnight fast in all CKD patients. Serum glucose, creatinine, urea, LDL cholesterol, and triglyceride concentrations were assessed by an oxidase-based technique at Roche/ Hitachi Modular System (Mannheim, Germany) in the biochemistry laboratories.
Statistical analysis
The Statistical Package for Social Sciences for Windows version 15.0 (SPSS, Chicago, IL, USA) was used for statistical analyses. Data are expressed as mean ± standard deviation. Dichotomous variables were compared using the chi-squared test. Statistical differences between parametric data of two groups were analyzed using the Student's t-test. The Mann-Whitney U test was used to determine differences between nonparametric data. Linear associations between continuous variables were assessed using the Spearman correlation test. A p value <0.05 was considered significant for all tests.
Results

Demographic Characteristics
A total of 3 of 313 (0.95 %) Caucasian CKD patients were diagnosed of Fabry disease in primary screening (patients 1, 5, 11). All the three were males and thus, the prevalence of Fabry disease in CKD males was 1.80% (Table 1) . Family screening of 73 family members from the 3 index patients disclosed that 8/73 (10.9%) had Fabry disease. Index patient 1 had 7 family members (4 male, 3 female) with both CKD and Fabry disease ( Figure 1 ) and index patient 11 had one daughter (patient 10) with both CKD and Fabry disease. Baseline demo- Tables 2 and 3. 7 out of 11 Fabry patients were male and 4 were female. As expected Fabry patients had more frequently symptoms associated with Fabry disease than CKD patients without Fabry disease.
Fabry Patient Symptoms
Median age at onset of first symptoms of Fabry disease was lower in males than in females (26 years vs 38 years, re-had severe episodic abdominal pain attacks and proteinuria, hence they were misdiagnosed as familial Mediterranean fever (FMF) and secondary amyloidosis even though they did not have FMF gene mutations. Kidney biopsy in the three siblings disclosed glomerular lipid vacuoles by that appeared empty with hematoxylin eosin and stained with oil-red 10 ( Figure  2a,b) . Electron microscopy revealed zebra bodies and myelin figures in podocytes ( Figure  2c ), but no evidence of amyloidosis. 
Treatment and follow-up
Of 11 patients with Fabry disease, 6 males (patients 1-6) started agalsidase-α 0.2 mg/kg/2 weeks and 1 male (patient 11) started agalsidase-β 1.0 mg/kg/2 weeks as ERT along with previously prescribed re n i n -a n g i o t e ns i n -a l d o s t e ro n e blockers (RAAS blockers) ( Table  4) . Patient 1 also started non-dihyropyridine calcium channel blocker (diltiazem 90 mg/day) to decrease proteinuria. Female patients did not accept ERT and they are being monitored. No patient developed anti-agalsidase antibody after 6 months of ERT.
No drug-related adverse events were observed in 6 patients, however patient 5 developed a mild infusion reaction including fever, malaise and skin rash that responded to slowing infusion, methylprednisolone, and anti-histaminic medication.
Discussion
The main findings of the present study were as follows: 1) the prevalence of Fabry disease was found to 0.95% (3/313) in a selected Turkish CKD cohort, 2) FMF was a frequent misdiagnosis that delayed the final diagnosis by about 5 years.
The diagnosis of Fabry disease is frequently delayed, as illustrated by the present report and Registry data [12] . In some cases this is due to misdiagnosis. In the present study, patients 1, 3 and 4 had severe episodic abdominal pain attacks and proteinuria, hence they were misdiagnosed as familial Mediterranean fever (FMF) and secondary amyloidosis despite later shown that neither a FMF gene mutation nor pathologic evidence of amyloidosis were present. Both FD and FMF patients might exhibit similar symptoms and clinical manifestations. In Turkey, patients with FMF have recurrent episodes of fever, abdominal pain, joint pain, and gastrointestinal disorders as well as kidney damage. Recently, 23 of 177 (13%) patients with symptoms of FMF were found to have α-Gal A deficiency in the Central Anatolia region of Turkey [13] . These results suggest that Fabry disease may be misdiagnosed as FMF in endemic regions and should be suspected especially in patients with symptoms of FMF without FMF gene mutation.
Most of our male patients with Fabry disease had severe and debilitating neuropathic pain. Their pain crises frequently coincided with warm weather which might be associated with increased body temperature, as previously described in Fabry disease [6, 14] . The beneficial effect of ERT on neuropathic Fabry pain within 6 months was reported by several authors [15, 16] . In the present study, after 6 months of ERT, all of our male patients with Fabry disease reported improvement in neuropathic pain.
Proteinuria, especially if >0.5 g/24h, is a risk factor for CKD progression in Fabry disease, even in patients receiving ERT [17, 18] . In this regard, 4/7 (57%) males already proteinuria above 0.5 g/24h when Fabry disease was diagnosed. Interestingly, RAAS blockers were recently found to be associated with stabilization of GFR when used in conjunction with ERT if proteinuria decreased below 0.5 g/day [19] .The GLA gene mutation of patient 5 has not been previously defined in the literature. This variant was not found in 500 clinical exome sequencing data of our patients. It was reported as a likely pathogenic variant by Mutation Taster software. In this regard, the presence of cornea verticillata, hypohidrosis and neuropathic pain are consistent with classical Fabry disease. However, the α-Gal A activity was just below the cut-off point and lyso-Gb levels were not available. The main limitation of the study was the small sample size. Another limitation is that the screening threshold for α-Gal A activity may have been too low. Two male siblings of an index case had enzymatic activity just above the threshold, despite Fabry symptoms, and genetic and histological evidence of Fabry disease. Thus, we may have missed some male Fabry patients, in addition to the well known fact that females may be missed in enzymatic screening efforts. Indeed, no female was diagnosed in the original CKD screening. Only the combination of genetic and enzymatic studies allowed the diagnosis of female family members of the index male patients found in the original CKD screening.
Conclusion
Our data demonstrated that Fabry disease was not uncommon among selected patients with CKD and support the ERBP recommendation to screen for Fabry disease in CKD patients in whom the etiology is unclear. Fabry disease should be considered in CKD patients with unknown origin and appropriate physical examination including eye, cardiovascular and central nervous system examination should be performed. Another population that merits special attention is that with nephropathy and abdominal pain without FMF gene mutation.
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